Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Developed in consultation with clinicians and patients for an enhanced user experience
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
The company will also share results in two additional posters for deuruxolitinib
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Subscribe To Our Newsletter & Stay Updated
